Private Market View

medimo

Tokyo, Japan · Founded 2022 · Acquired/Merged (Operating Subsidiary)

Last price · $/share
Implied valuation
$4.3M
Total raised
$1.1M
Last round

Key facts

  • medimo’s last known valuation is $4.3M (Jan 2025).
  • It has raised $1.1M; the latest was Merger/Acquisition in Feb 2026.
  • Status: Acquired/Merged (Operating Subsidiary).
Free account
See the evidence behind this price
  • ·Watchlist + deal alerts for medimo
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for medimo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About medimo

Developer of an artificial intelligence tool designed to create medical record manuscripts from medical audio. The company tool automatically generates medical records in subjective, objective, assessment, and plan formats using audio input of consultation conversations and artificial intelligence summaries, enabling doctors to concentrate on their work.

Sector
Healthcare
HQ
Tokyo, Japan
Founded
2022
Employees
20
Ownership
Acquired/Merged (Operating Subsidiary)
PA Mark — not yet priced

medimo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in medimo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on medimo in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.